Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | CDKN2A |
Variant | positive |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | CDKN2A positive indicates the presence of the CDKN2A gene, mRNA, and/or protein. |
Associated Drug Resistance |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A pos RB1 inact mut | glioblastoma | resistant | Palbociclib | Preclinical - Patient cell culture | Actionable | In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607). | 22711607 |
Molecular Profile | Protein Effect | Treatment Approaches |
---|---|---|
CDKN2A positive | unknown | |
CDKN2A pos RB1 inact mut |